Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in older patients, according to an analysis of randomized clinical trials in the New England Journal of Medicine. Read more here.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder